医学
多发性骨髓瘤
自体干细胞移植
维持疗法
队列
内科学
移植
外科
肿瘤科
临床试验
化疗
作者
Dhauna Karam,Morie Abraham Gertz,Martha Q. Lacy,Angela A. Dispenzieri,Suzanne R. Hayman,David Dingli,Francis K. Buadi,Prashant Kapoor,Taxiarchis Kourelis,Rahma M. Warsame,William J. Hogan,Shaji Kunnathu Kumar
标识
DOI:10.1038/s41409-022-01631-8
摘要
Based on phase 3 trials, maintenance therapy after autologous stem cell transplantation (ASCT) has become the standard of care in multiple myeloma (MM). We examined the trends in maintenance therapy in a large group of patients (2530) transplanted at a single institution over two decades. Majority (n = 1958; 77%) had an ASCT within 12 months of diagnosis (early ASCT). Maintenance was employed in 39% of the patients; 42% among early ASCT and 30.5% among delayed ASCT. Most common maintenance approach was an IMiD (61%), followed by a PI (31%), or a PI + IMiD (4%). Patients with high-risk FISH received PI-based maintenance more frequently. The PFS was superior with maintenance (36 vs. 22 months, p < 0.001); 37 vs. 25 months for early ASCT (p < 0.001) and 29 vs. 17 months for delayed ASCT (p = 0.0008). OS from ASCT was higher with maintenance for the whole cohort at 93 vs. 73 months (p < 0.001). OS from diagnosis was also better for the whole cohort with maintenance therapy, 112 vs. 93 months (p < 0.001). The improvement in PFS and OS was seen in high-risk and standard risk disease. The experience with maintenance therapy post ASCT for myeloma in a non-clinical trial setting confirms the findings from the phase 3 trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI